Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioHarvest Sciences ( (BHST) ) is now available.
BioHarvest Sciences will participate in the 38th Annual Roth Conference in Dana Point, California, from March 22 to 24, 2026, where CEO Ilan Sobel will hold one-on-one meetings with institutional investors. The appearance comes after a successful Q4 2025 financing round that fully funded the company’s near-term capital expenditures and positions it to accelerate growth across its CDMO and consumer product businesses.
Management highlighted that BioHarvest now serves more than 85,000 direct customers on the consumer side and has secured anchor CDMO research partnerships, which it believes set the stage for significant growth milestones in 2026. The company aims to leverage its novel plant-based compounds to enhance its competitiveness in health and wellness markets and to reinforce its profile among sophisticated investors seeking exposure to innovative therapeutic and nutraceutical solutions.
The most recent analyst rating on (BHST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company specializing in Botanical Synthesis, a patented platform that produces plant-based compounds without growing the whole plant. The company operates two main business lines: a CDMO segment that develops novel plant-based compounds for third-party clients, and a consumer division focused on proprietary nutraceutical and dietary supplement products targeting health and wellness markets.
Average Trading Volume: 41,931
Technical Sentiment Signal: Buy
Current Market Cap: $102.2M
See more insights into BHST stock on TipRanks’ Stock Analysis page.